Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia

Objectives: To estimate the prevalence of four Statin Benefit Groups (SBG) according to the 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol, in a population of the Caribbean region of Colombia enrolled to DTC program Mutual SER-EPS in 2015 Methods: Data on a history of hyp...

Full description

Autores:
Miranda, P. A.
Salcedo Mejía, F. E.
Paz-Wilches, J.
De La Hoz, F.
Alvis-Guzmán, N.
Tipo de recurso:
http://purl.org/coar/resource_type/c_816b
Fecha de publicación:
2019
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/5210
Acceso en línea:
https://hdl.handle.net/11323/5210
https://repositorio.cuc.edu.co/
Palabra clave:
Statin
Cholesterol
Región Caribe
Colombia
Rights
openAccess
License
CC0 1.0 Universal
id RCUC2_0b5a367b532e1e63e5b6716fcc29c741
oai_identifier_str oai:repositorio.cuc.edu.co:11323/5210
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.spa.fl_str_mv Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
title Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
spellingShingle Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
Statin
Cholesterol
Región Caribe
Colombia
title_short Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
title_full Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
title_fullStr Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
title_full_unstemmed Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
title_sort Prevalence of four statin benefit groups in a population of the Caribbean region of Colombia
dc.creator.fl_str_mv Miranda, P. A.
Salcedo Mejía, F. E.
Paz-Wilches, J.
De La Hoz, F.
Alvis-Guzmán, N.
dc.contributor.author.spa.fl_str_mv Miranda, P. A.
Salcedo Mejía, F. E.
Paz-Wilches, J.
De La Hoz, F.
Alvis-Guzmán, N.
dc.subject.spa.fl_str_mv Statin
Cholesterol
Región Caribe
Colombia
topic Statin
Cholesterol
Región Caribe
Colombia
description Objectives: To estimate the prevalence of four Statin Benefit Groups (SBG) according to the 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol, in a population of the Caribbean region of Colombia enrolled to DTC program Mutual SER-EPS in 2015 Methods: Data on a history of hyperlipidemia was collected by study investigators at including adults patients enrolled to DTC program Mutual SER-EPS in 2015 (N = 64,667) with ICD-10 diagnosis of hyperlipidemia (E78), or with a personal history of hyperlipidemia; or with abnormal lipid profile; or patients under treatment with lipid-lowering drugs. The four SBG were comprised adult patients $21 years of age with clinical atherosclerotic cardiovascular disease (ASCVD) (SBG1); adults $21 years of age with LDL-C $190 mg/dL (not due to secondary modifiable causes) (SBG2); adults aged 40 to 75 years without ASCVD, but with diabetes and with LDL-C 70 to 189 mg/dL (SBG3); and adults ages 40 to 75 years without ASCVD or diabetes, with LDL-C 70 to 189 mg/dL, and an estimated 10-year risk for ASCVD of $ 20% as determined by the Framingham Risk Score (SBG4). The prevalence of statin use by SBG and factors associated with statin use were estimated. Results: The prevalence of SBG1, SBG2, SBG3 and SBG4 in patients enrolled to DTC program Mutual SER-EPS in 2015 were 4.6% (2,985), 0.5% (337), 2.5% (1,633) and 1.3% (891), respectively. The prevalence of statin use in SBG1, SBG2, SBG3 and SBG4 were 69.1% (2,064), 40.6% (137), 47% (768) and 59.1% (463), respectively. Arterial hypertension (OR: 2.70; 95% IC 1.70-4.28) and personal history of ASCVD (OR: 3.43; 95% IC 2.15-5.46) were very significantly associated with statin use. Conclusions: The prevalence of SBG and statin use in patients enrolled to DTC program Mutual SEREPS in 2015 were 9% (5,846) and 58.7% (3,432), respectively.
publishDate 2019
dc.date.accessioned.none.fl_str_mv 2019-08-28T16:14:46Z
dc.date.available.none.fl_str_mv 2019-08-28T16:14:46Z
dc.date.issued.none.fl_str_mv 2019
dc.type.spa.fl_str_mv Pre-Publicación
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_816b
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/preprint
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ARTOTR
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_816b
status_str acceptedVersion
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/5210
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
url https://hdl.handle.net/11323/5210
https://repositorio.cuc.edu.co/
identifier_str_mv Corporación Universidad de la Costa
REDICUC - Repositorio CUC
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.spa.fl_str_mv CC0 1.0 Universal
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/publicdomain/zero/1.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv CC0 1.0 Universal
http://creativecommons.org/publicdomain/zero/1.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.publisher.spa.fl_str_mv Universidad de la Costa
institution Corporación Universidad de la Costa
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/e012f755-4727-400c-9002-d0829d6c8dee/download
https://repositorio.cuc.edu.co/bitstreams/cea11da4-7625-4b11-a304-fc98749c55fa/download
https://repositorio.cuc.edu.co/bitstreams/c969b30b-76ba-4424-bdaf-8c6983fc659d/download
https://repositorio.cuc.edu.co/bitstreams/94eaa80b-78ba-49d6-bd1e-73421e02f52c/download
https://repositorio.cuc.edu.co/bitstreams/10321b20-e0d0-4b21-81b6-12b63b0e177b/download
bitstream.checksum.fl_str_mv 57a191770ce238647696e66c9de4cc27
42fd4ad1e89814f5e4a476b409eb708c
8a4605be74aa9ea9d79846c1fba20a33
5751b2b9745c3bb5d635aa6818a11494
2e88d337c6c36ac4653666235a2c4184
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1811760710584107008
spelling Miranda, P. A.Salcedo Mejía, F. E.Paz-Wilches, J.De La Hoz, F.Alvis-Guzmán, N.2019-08-28T16:14:46Z2019-08-28T16:14:46Z2019https://hdl.handle.net/11323/5210Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objectives: To estimate the prevalence of four Statin Benefit Groups (SBG) according to the 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol, in a population of the Caribbean region of Colombia enrolled to DTC program Mutual SER-EPS in 2015 Methods: Data on a history of hyperlipidemia was collected by study investigators at including adults patients enrolled to DTC program Mutual SER-EPS in 2015 (N = 64,667) with ICD-10 diagnosis of hyperlipidemia (E78), or with a personal history of hyperlipidemia; or with abnormal lipid profile; or patients under treatment with lipid-lowering drugs. The four SBG were comprised adult patients $21 years of age with clinical atherosclerotic cardiovascular disease (ASCVD) (SBG1); adults $21 years of age with LDL-C $190 mg/dL (not due to secondary modifiable causes) (SBG2); adults aged 40 to 75 years without ASCVD, but with diabetes and with LDL-C 70 to 189 mg/dL (SBG3); and adults ages 40 to 75 years without ASCVD or diabetes, with LDL-C 70 to 189 mg/dL, and an estimated 10-year risk for ASCVD of $ 20% as determined by the Framingham Risk Score (SBG4). The prevalence of statin use by SBG and factors associated with statin use were estimated. Results: The prevalence of SBG1, SBG2, SBG3 and SBG4 in patients enrolled to DTC program Mutual SER-EPS in 2015 were 4.6% (2,985), 0.5% (337), 2.5% (1,633) and 1.3% (891), respectively. The prevalence of statin use in SBG1, SBG2, SBG3 and SBG4 were 69.1% (2,064), 40.6% (137), 47% (768) and 59.1% (463), respectively. Arterial hypertension (OR: 2.70; 95% IC 1.70-4.28) and personal history of ASCVD (OR: 3.43; 95% IC 2.15-5.46) were very significantly associated with statin use. Conclusions: The prevalence of SBG and statin use in patients enrolled to DTC program Mutual SEREPS in 2015 were 9% (5,846) and 58.7% (3,432), respectively.Miranda, P. A.Salcedo Mejía, F. E.Paz-Wilches, J.De La Hoz, F.Alvis-Guzmán, N.engUniversidad de la CostaCC0 1.0 Universalhttp://creativecommons.org/publicdomain/zero/1.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2StatinCholesterolRegión CaribeColombiaPrevalence of four statin benefit groups in a population of the Caribbean region of ColombiaPre-Publicaciónhttp://purl.org/coar/resource_type/c_816bTextinfo:eu-repo/semantics/preprinthttp://purl.org/redcol/resource_type/ARTOTRinfo:eu-repo/semantics/acceptedVersionPublicationORIGINALPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdfPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdfapplication/pdf7176https://repositorio.cuc.edu.co/bitstreams/e012f755-4727-400c-9002-d0829d6c8dee/download57a191770ce238647696e66c9de4cc27MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8701https://repositorio.cuc.edu.co/bitstreams/cea11da4-7625-4b11-a304-fc98749c55fa/download42fd4ad1e89814f5e4a476b409eb708cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstreams/c969b30b-76ba-4424-bdaf-8c6983fc659d/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdf.jpgPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdf.jpgimage/jpeg60203https://repositorio.cuc.edu.co/bitstreams/94eaa80b-78ba-49d6-bd1e-73421e02f52c/download5751b2b9745c3bb5d635aa6818a11494MD55TEXTPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdf.txtPrevalence of four statin benefit groups in a population of the Caribbean region of Colombia.pdf.txttext/plain2077https://repositorio.cuc.edu.co/bitstreams/10321b20-e0d0-4b21-81b6-12b63b0e177b/download2e88d337c6c36ac4653666235a2c4184MD5611323/5210oai:repositorio.cuc.edu.co:11323/52102024-09-17 10:44:55.666http://creativecommons.org/publicdomain/zero/1.0/CC0 1.0 Universalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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